Arvinas Inc. reported an automatic sale of common stock by Chief Medical Officer Noah Berkowitz on February 13, 2026. According to the Form 4 filed with the Securities and Exchange Commission, 5,685 shares were sold at $11.89 per share, producing total proceeds of $67,594.
The filing specifies this disposition was executed by the company to meet tax withholding requirements tied to the vesting and settlement of one-quarter of Berkowitz's restricted stock units (RSUs) that were granted on February 13, 2025. The filing also notes the sale was not a discretionary transaction by Berkowitz.
Following the transfer of shares, Berkowitz directly holds 163,938 shares of Arvinas. At the time of the transaction Arvinas common stock was trading around $11.82 per share.
Company position and near-term schedule
The filing and related disclosures highlight that Arvinas currently reports a balance sheet with more cash than debt. The company is scheduled to announce its next earnings results on February 24. Market data referenced in the filing shows notable price swings for the stock: a decline of nearly 10% over the past week, while the shares have appreciated approximately 65% over the prior six months.
Context and interpretation
The transaction was an automatic, corporate-executed sale to satisfy tax obligations arising from RSU vesting. The Form 4 explicitly indicates the sale was not initiated at the executive's discretion. That distinction is material for investors tracking insider activity, as mandatory withholdings can produce sales that do not reflect active judgment about company valuation or near-term prospects.
What is known and what is not
- The exact number of vested RSUs corresponding to the withheld 25% is described in the filing as tied to the grant dated February 13, 2025.
- The transaction price, share count sold, remaining direct ownership, and the reason for sale are disclosed in the SEC filing.
- No discretionary intent to sell by the officer is stated in the filing; other motives or plans are not detailed.
Takeaway
This filing records a routine, tax-related share sale by a senior officer rather than a voluntary divestiture. Investors tracking insider transactions should note the procedural nature of the sale, the officer's still-substantial direct ownership, the company's reported cash surplus relative to debt, and the impending earnings release that may influence short-term volatility.